Markets:

Overview

News

Currencies

International

Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

23.48 +0.69 (+3.03%)

Streaming Delayed Price Updated: 11:03 AM EDT, Mar 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals

April 08, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Why Mark Minervini may look into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) ↗

April 05, 2025

A fundamental and technical analysis of (NASDAQ:CPRX): Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for high growth investing?

Via Chartmill

Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday ↗

April 03, 2025

Via The Motley Fool

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Why NASDAQ:CPRX qualifies as a high growth stock. ↗

February 13, 2025

A fundamental analysis of (NASDAQ:CPRX): Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s Growth Prospects.

Via Chartmill

Unlocking the Growth Potential of NASDAQ:CPRX. ↗

February 11, 2025

A fundamental analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.

Via Chartmill

Exploring NASDAQ:CPRX's high growth characteristics. ↗

February 10, 2025

CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for high growth investors. Here's why. Full fundamental and technical analysis of (NASDAQ:CPRX).

Via Chartmill

Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). ↗

March 31, 2025

A fundamental analysis of (NASDAQ:CPRX): Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for growth investing?

Via Chartmill

CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is showing decent growth, but is still valued reasonably. ↗

March 28, 2025

CATALYST PHARMACEUTICALS INC could be undervalued. NASDAQ:CPRX is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.

Via Chartmill

Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for growth investing? ↗

March 25, 2025

A fundamental analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.

Via Chartmill

Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio? ↗

March 23, 2025

Top performers last week: DGNX (108.29%), NEXT (25.07%), CELH (21.60%), SIG (21.08%), NFE (20.63%), MRP (16.61%), ARQT (16.35%), LCID (15.79%), CPRX (15.27%), STNE (14.20%). Are they in your...

Via Benzinga

Beyond The Numbers: 6 Analysts Discuss Catalyst Pharmaceuticals Stock ↗

February 04, 2025

Via Benzinga

Unlocking the Growth Potential of NASDAQ:CPRX. ↗

January 22, 2025

Exploring CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s CANSLIM characteristics.

Via Chartmill

For those who appreciate value investing, CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a compelling option with its solid fundamentals. ↗

March 21, 2025

Uncover the potential of CATALYST PHARMACEUTICALS INC, an undervalued stock. NASDAQ:CPRX maintains a strong financial position and offers an appealing valuation.

Via Chartmill

Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a CANSLIM stock. ↗

March 06, 2025

A fundamental analysis of (NASDAQ:CPRX): Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) a Fit for Growth Investing Strategies?

Via Chartmill

Looking for growth without the hefty price tag? Consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). ↗

March 06, 2025

CATALYST PHARMACEUTICALS INC was identified as an affordable growth stock. NASDAQ:CPRX is showing great growth, but also scores well on profitability. At the same time it seems to be priced...

Via Chartmill

Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) on the Verge of a Major Breakout as a Strong Growth Stock? ↗

March 06, 2025

Based on a technical and fundamental analysis of NASDAQ:CPRX we are exploring the Growth Potential of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) as It Nears a Breakout.

Via Chartmill

Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference

March 04, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) suited for growth investing? ↗

March 04, 2025

A fundamental analysis of (NASDAQ:CPRX): Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) suited for growth investing?

Via Chartmill

Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today ↗

February 27, 2025

The drugmaker confirmed there's a strong market for two of its treatments.

Via The Motley Fool

Catalyst Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

February 27, 2025

Via Benzinga

CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

February 27, 2025

CATALYST PHARMACEUTICALS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:CPRX showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 26, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Investors should take note of NASDAQ:CPRX, a growth stock that remains attractively priced. ↗

February 12, 2025

Based on Fundamental Analysis it can be said that NASDAQ:CPRX is a growth stock which is not overvalued.

Via Chartmill

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

February 12, 2025

The Company will Host a Conference Call and Webcast on February 27, 2025, at 8:30 AM ET

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Why NASDAQ:CPRX Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

February 07, 2025

Based on a technical and fundamental analysis of NASDAQ:CPRX we can say: CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a strong growth stock, setting up for a breakout.

Via Chartmill

NASDAQ:CPRX: good value for what you're paying. ↗

February 05, 2025

Uncover the potential of CATALYST PHARMACEUTICALS INC, an undervalued stock. NASDAQ:CPRX maintains a strong financial position and offers an appealing valuation.

Via Chartmill

This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

February 04, 2025

Via Benzinga

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies

January 23, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

While growth is established for NASDAQ:CPRX, the stock's valuation remains reasonable. ↗

January 22, 2025

Investors seeking growth at a reasonable cost should explore CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.